Hypoxic challenge testing (HCT) in COPD and pulmonary hypertension (PH)

N. A. Marks, C. I. Mordin, H. C. Tighe, R. J. Shiner, P. W. Ind (London, United Kingdom)

Source: Annual Congress 2004 - Exercise and gas exchange
Session: Exercise and gas exchange
Session type: Thematic Poster Session
Number: 2070
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
N. A. Marks, C. I. Mordin, H. C. Tighe, R. J. Shiner, P. W. Ind (London, United Kingdom). Hypoxic challenge testing (HCT) in COPD and pulmonary hypertension (PH). Eur Respir J 2004; 24: Suppl. 48, 2070

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Impact of borderline (BL) pulmonary hypertension (PH) in chronic lung diseases (CLD).
Source: Virtual Congress 2020 – Pulmonary hypertension in lung diseases
Year: 2020


Pulmonary hypertension (PH) and features of pulmonary circulation in patient with lung sarcoidosis (LS)
Source: Eur Respir J 2006; 28: Suppl. 50, 354s
Year: 2006

Pulmonary arterial hypertension (PAH) in patients with lung sarcoidosis (LS)
Source: Annual Congress 2008 - Clinical aspects in the management of sarcoidosis
Year: 2008


Pulmonary hypertension (PH) associated with haemolysis
Source: Annual Congress 2008 - Pulmonary hypertension I
Year: 2008

Role of tadalafil in patients with hypoxia / lung disease induced (group 3) pulmonary hypertension
Source: International Congress 2016 – Pulmonary hypertension: the clinic I
Year: 2016

The role of secondary pulmonary hypertension (SPH) in the limited exercise tolerance of patients with interstitial lung disease (ILD)
Source: Eur Respir J 2005; 26: Suppl. 49, 560s
Year: 2005

Comparison of pulmonary hypertension (PH) associated to chronic lung disease to other PH groups
Source: International Congress 2016 – Pulmonary hypertension in lung disease
Year: 2016

Inflammatory biomarkers in patients with COPD and pulmonary hypertension (PH).
Source: International Congress 2019 – Pulmonary hypertension with lung diseases and experimental pulmonary hypertension
Year: 2019


Pulmonary artery pressure (PAP) reduction by systemic and inhaled nitroglycerin (NTG) in an isolated rabbit lung model of pulmonary hypertension (PH)
Source: Eur Respir J 2003; 22: Suppl. 45, 270s
Year: 2003

Pulmonary hypertension (PH) in chronic hemodialysis (CHD) patients is associated with inflammatory markers and volume overload
Source: Annual Congress 2013 –Pulmonary circulation: clinical science and treatment
Year: 2013


Effects of amlodipine on pulmonary haemodynamics in pulmonary hypertension (PH) secondary to chronic obstructive pulmonary disease (COPD)
Source: Eur Respir J 2002; 20: Suppl. 38, 27s
Year: 2002

Treatment of pulmonary hypertension (PH) and sickle cell disease (SCD) with sildenafil (SILD) therapy (walk-phasst): interim report
Source: Annual Congress 2009 - Clinical management of pulmonary arterial hypertension
Year: 2009


Contrasting physiological responses to the six minute walk test in patients with chronic thromboembolic pulmonary hypertension (CTEPH) and idiopathic pulmonary arterial hypertension (IPAH)
Source: International Congress 2016 – Pulmonary hypertension: exercise, haemodynamics, and physiology
Year: 2016


Relationship between pulmonary hypertension (PH) and lung function in severe COPD patients
Source: Eur Respir J 2001; 18: Suppl. 33, 252s
Year: 2001

Arterial hypertension (AH) and endothelial function (EF) in patients with COPD
Source: Annual Congress 2011 - COPD mechanisms
Year: 2011

Pulmonary rehabilitation (PR) outcomes in chronic obstructive pulmonary disease (COPD) compared with interstitial lung disease (ILD)
Source: Annual Congress 2011 - Pulmonary rehabilitation: looking at alternative approaches and alternative populations beyond COPD
Year: 2011

Comparison of subcutaneous (sc) treprostinil use for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) in 2 Belgian centers
Source: Annual Congress 2010 - Pulmonary venous thromboembolic disease
Year: 2010


Pulmonary arterial hypertension (PAH) among end state renal disease (ESRD) patients under chronic hemodyalisis (HD)
Source: Eur Respir J 2007; 30: Suppl. 51, 345s
Year: 2007

Effects of a respiratory rehabilitation program over pulmonary hypertension (PH) and other right ventricular function measurements in a chronic obstructive pulmonary disease (COPD) population
Source: Virtual Congress 2020 – The multiple facets of pulmonary rehabilitation and chronic respiratory care
Year: 2020


Nitric oxide and oxygen inhalation during exercise in patients with chronic obstructive lung disease (COPD) and secondary pulmonary hypertension (PH)
Source: Eur Respir J 2001; 18: Suppl. 33, 83s
Year: 2001